Your browser doesn't support javascript.
loading
Racial Differences in Donor-Derived Cell-Free DNA and Mitochondrial DNA After Heart Transplantation, on Behalf of the GRAfT Investigators.
Shah, Palak; Agbor-Enoh, Sean; Lee, Seiyon; Andargie, Temesgen E; Sinha, Shashank S; Kong, Hyesik; Henry, Lawrence; Park, Woojin; McNair, Erick; Tchoukina, Inna; Shah, Keyur B; Najjar, Samer S; Hsu, Steven; Rodrigo, Maria E; Jang, Moon Kyoo; Marboe, Charles; Berry, Gerald J; Valantine, Hannah A.
Afiliação
  • Shah P; Heart Failure, Mechanical Circulatory Support & Transplant, Inova Schar Heart and Vascular, Falls Church, VA (P.S., S.S.S., L.H., E.M.).
  • Agbor-Enoh S; Genomic Research Alliance for Transplantation (GRAfT), Bethesda, MD (P.S., S.A.-E., T.E.A., M.K.J., H.A.V.).
  • Lee S; Genomic Research Alliance for Transplantation (GRAfT), Bethesda, MD (P.S., S.A.-E., T.E.A., M.K.J., H.A.V.).
  • Andargie TE; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD (S.A.-E., S.H.).
  • Sinha SS; Applied Precision Genomics, National Heart, Lung and Blood Institute, Bethesda, MD (S.A.-E., T.E.A., H.K., W.P., M.K.J.).
  • Kong H; Volgenau School of Engineering, George Mason University, Fairfax, VA (S.L.).
  • Henry L; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD (S.A.-E., S.H.).
  • Park W; Applied Precision Genomics, National Heart, Lung and Blood Institute, Bethesda, MD (S.A.-E., T.E.A., H.K., W.P., M.K.J.).
  • McNair E; Heart Failure, Mechanical Circulatory Support & Transplant, Inova Schar Heart and Vascular, Falls Church, VA (P.S., S.S.S., L.H., E.M.).
  • Tchoukina I; Applied Precision Genomics, National Heart, Lung and Blood Institute, Bethesda, MD (S.A.-E., T.E.A., H.K., W.P., M.K.J.).
  • Shah KB; Heart Failure, Mechanical Circulatory Support & Transplant, Inova Schar Heart and Vascular, Falls Church, VA (P.S., S.S.S., L.H., E.M.).
  • Najjar SS; Applied Precision Genomics, National Heart, Lung and Blood Institute, Bethesda, MD (S.A.-E., T.E.A., H.K., W.P., M.K.J.).
  • Hsu S; Heart Failure, Mechanical Circulatory Support & Transplant, Inova Schar Heart and Vascular, Falls Church, VA (P.S., S.S.S., L.H., E.M.).
  • Rodrigo ME; The Pauley Heart Center, Virginia Commonwealth University, Richmond (I.T., K.B.S.).
  • Jang MK; The Pauley Heart Center, Virginia Commonwealth University, Richmond (I.T., K.B.S.).
  • Marboe C; Advanced Heart Failure Program, Medstar Heart and Vascular Institute, Washington Hospital Center, Washington DC (S.S.N., M.E.R.).
  • Berry GJ; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD (S.A.-E., S.H.).
  • Valantine HA; Advanced Heart Failure Program, Medstar Heart and Vascular Institute, Washington Hospital Center, Washington DC (S.S.N., M.E.R.).
Circ Heart Fail ; 17(4): e011160, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38375637
ABSTRACT

BACKGROUND:

Black heart transplant patients are at higher risk of acute rejection (AR) and death than White patients. We hypothesized that this risk may be associated with higher levels of donor-derived cell-free DNA (dd-cfDNA) and cell-free mitochondrial DNA.

METHODS:

The Genomic Research Alliance for Transplantation is a multicenter, prospective, longitudinal cohort study. Sequencing was used to quantitate dd-cfDNA and polymerase chain reaction to quantitate cell-free mitochondrial DNA in plasma. AR was defined as ≥2R cellular rejection or ≥1 antibody-mediated rejection. The primary composite outcome was AR, graft dysfunction (left ventricular ejection fraction <50% and decrease by ≥10%), or death.

RESULTS:

We included 148 patients (65 Black patients and 83 White patients), median age was 56 years and 30% female sex. The incidence of AR was higher in Black patients compared with White patients (43% versus 19%; P=0.002). Antibody-mediated rejection occurred predominantly in Black patients with a prevalence of 20% versus 2% (P<0.001). After transplant, Black patients had higher levels of dd-cfDNA, 0.09% (interquartile range, 0.001-0.30) compared with White patients, 0.05% (interquartile range, 0.001-0.23; P=0.003). Beyond 6 months, Black patients showed a persistent rise in dd-cfDNA with higher levels compared with White patients. Cell-free mitochondrial DNA was higher in Black patients (185 788 copies/mL; interquartile range, 101 252-422 133) compared with White patients (133 841 copies/mL; interquartile range, 75 346-337 990; P<0.001). The primary composite outcome occurred in 43% and 55% of Black patients at 1 and 2 years, compared with 23% and 27% in White patients, P<0.001. In a multivariable model, Black patient race (hazard ratio, 2.61 [95% CI, 1.35-5.04]; P=0.004) and %dd-cfDNA (hazard ratio, 1.15 [95% CI, 1.03-1.28]; P=0.010) were associated with the primary composite outcome.

CONCLUSIONS:

Elevated dd-cfDNA and cell-free mitochondrial DNA after heart transplant may mechanistically be implicated in the higher incidence of AR and worse clinical outcomes in Black transplant recipients. REGISTRATION URL https//www.clinicaltrials.gov; Unique identifier NCT02423070.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Coração / Ácidos Nucleicos Livres / Insuficiência Cardíaca Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Circ Heart Fail Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Coração / Ácidos Nucleicos Livres / Insuficiência Cardíaca Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Circ Heart Fail Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2024 Tipo de documento: Article